"Designing Growth Strategies is in our DNA"
The global non-steroidal anti-inflammatory drugs (NSAIDs) market size stood at USD 15.58 billion in 2019 and is projected to reach USD 24.35 billion by 2027, exhibiting a CAGR of 5.8% during the forecast period.
Chronic pain causes a major health and economic burden owing to the loss of productivity and treatment cost. Non-steroidal anti-inflammatory drugs are primarily used for the treatment of pain and inflammation. The rising prevalence of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, migraine, and others is increasing the uptake of these drugs. With the increasing number of prescriptions, these have become the most commonly used drugs across the globe. According to a press release of Endo International plc, about 84 million NSAIDs prescriptions are written annually in the U.S. This is anticipated to augment the market growth. Furthermore, positive recommendations from the Centers for Disease Control and Prevention on the use of non-opioid drugs for the treatment of pain will help the market to flourish. With the launch of new products, the market is expected to grow further. In May 2019, Perrigo Company plc announced the FDA approval for Abbreviated New Drug Application (ANDA) referencing to Voltaren Gel. This is expected to positively impact the NSAIDs market.
Request a Free sample to learn more about this report.
Research on COX-2 Inhibitors by Major Manufacturers to Boost Growth
One of the important market trends is the increasing research on selective cyclooxygenase-2 (COX-2) inhibitors. Presently available NSAIDs such as diclofenac and ibuprofen not only inhibit the activity of COX-2, but also of COX-1 resulting in undesirable side effects. Selective COX-2 inhibitors remain a challenging and grey area for the pharmaceutical companies. Currently, Celebrex manufactured by Pfizer is the only COX-2 inhibitor commercially available in the U.S. However, many pharmaceutical giants are now making significant investment to develop new COX-2 inhibitors for the treatment of pain and inflammation. For example, Crystal Genomics is conducting phase 3 clinical trial on CG100649, a dual COX-2 and carbonic anhydrase (CA) inhibitor for the treatment of osteoarthritis.
Rising Prevalence of Chronic Pain to Favor Growth
Increasing prevalence of pain and inflammation causing diseases is one of the leading factors driving the non-steroidal anti-inflammatory drugs market growth. Uptake of these drugs is rising gradually for the treatment of acute and chronic pain. Ibuprofen and diclofenac are the commonly prescribed drugs to provide relief form pain. According to the Centers for Disease Control and Prevention, in 2016, over 50 million adults in the U.S. had chronic pain and 19.6 million had high-impact chronic pain. This is expected to fuel the NSAIDs market growth during the forecast period. According to Institute of Medicine Report, chronic pain cost around USD 560 billion every year for medical care, disability services, and loss of productivity in the U.S. Active steps are being taken by the government to reduce this cost burden which is expected to boost the market.
Preference for NSAIDs over Opioids to Foster Market Growth
NSAIDs and opioids are the most commonly prescribed drugs for the treatment of mild to severe pain. However, use of opioids is associated with severe adverse events. Opioids safety thus remains a major concern receiving widespread attention owing to the increasing opioids-relation deaths. This has, in turn, led to an increasing preference for these drugs for the treatment of pain and a declined use of opioids. Furthermore, the American Academy of Family Physicians recommends the use of ibuprofen and naproxen as first line of treatment for mild to moderate pain. Similar positive recommendations are expected to boost the NSAIDs market growth.
Side Effects of NSAIDs are Likely to Hinder the Market Growth
Side effects from the uptake of NSAIDs such as allergic reactions, stomach ulcers, stomach-pain, dizziness, and others are expected to restrain the market growth. Owing to their easy availability and anti-inflammatory action, these drugs are among the most commonly prescribed medications. However, significant rise in NSAIDs-related gastrointestinal complications has been observed across the globe, which is a potential burden on the healthcare system. NSAIDs associated GI bleeding is the most common reason for the majority of emergency hospital admissions. Moreover, its complication is the most common drug side in the U.S. This is expected to negatively impact the non-steroidal anti-inflammatory drugs market revenue.
To know how our report can help streamline your business, Speak to Analyst
Arthritis Segment to Generate the Maximum Revenue
On the basis of disease indication, the market can be segmented into arthritis, migraine, ophthalmic diseases, and others. The arthritis segment is expected to dominate the market throughout the forecast period primarily due to the rising prevalence of rheumatoid arthritis and osteoarthritis. Apart from this, the increasing geriatric population and adoption of topical drugs for arthritis pain are expected to contribute to the expansion of the segment. The migraine segment is anticipated to grow owing to the increasing sales of Advil and the frequent occurrence of migraine. The ophthalmic diseases segment is projected to gain momentum owing to the increasing uptake of these drugs post eye surgery. They are extensively employed to reduce photophobia and pain after photorefractive surgery and reduce inflammation, and cystoid muscular edema post cataract surgery. Thus, the increasing number of eye surgeries is likely to augment the market. The others segment is expected to expand which can be attributable to the rising uptake of over-the-counter NSAIDs for the treatment of acute pain caused due to cramps, bursitis, ankylosing spondylitis, and rising prevalence of atopic dermatitis. In December 2016, Pfizer announced the FDA approval for Eucrisa for the treatment of atopic dermatitis, which, in turn, will expand this segment.
Oral Segment to Exhibit Maximum Growth
On the basis of route of administration, the market is segmented into oral and parenteral. The oral segment generated the maximum revenue in 2019. Factors attributable for the remarkable growth of this segment are availability of more drugs, increasing sales of Celebrex, and rising preference for COX-2 selective NSAIDs. The parenteral segment is likely to propel during the forecast period owing to the use of topical drops for ophthalmic diseases and higher sales of Voltaren gel.
Hospital Pharmacy Segment to Dominate the Market
In terms of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital segment accounted for the maximum portion of the market during 2019 owing to the increasing number of prescriptions for NSAIDs and favorable health reimbursement. Rising availability of over-the-counter (OTC) drugs, increasing demand for diclofenac and ibuprofen, and new product launches are projected to boost the retail pharmacy segment. In April 2018, Strides Pharma Inc. received the U.S. FDA approval for Ibuprofen OTC Capsules which is expected to augment the retail pharmacy segment. The online segment is anticipated to grow due to the rising adoption of e-commerce, increasing disposable incomes, and attractive discounts on online sales.
North America Non-steroidalSteroidal Anti-Inflammatory Drugs (NSAIDs) Market Size, 2019 (USD Billion)
To get more information on the regional analysis of this market, Request a Free sample
The non-steroidal anti-inflammatory drugs market size in North America stood at USD 6.86 billion in 2019. Strategic presence of major manufacturers, rising prevalence of arthritis, and increased research are the factors for the dominant share of North America. According to the Centers for Disease Control and Prevention, 78 million adults in the U.S. are estimated to have doctor-diagnosed arthritis by 2040. This is expected to fuel the market in North America during the forecast period. In Europe, the market for NSAIDs is anticipated to augment owing to the active government support, rising prevalence of migraine, and favorable health reimbursement. The Migraine Trust declared that every day, approximately 3000 migraine attacks occur for each million of the general population. It equates to around 190,000 migraine attacks in the U.K. every year. This is anticipated to foster the market in Europe. Increasing geriatric population, rising adoption of OTC NSAIDs, and less price as compared to biologics are poised to surge the market in Asia Pacific. The market in the Middle East & Africa and Latin America is projected to grow owing to the rising prevalence of inflammatory diseases and increasing health expenditure.
GSK and Pfizer to Account for the Leading Position
In terms of non-steroidal anti-inflammatory drugs market revenue, GSK accounted for the maximum portion of the market. Factors attributable for the dominant share of GSK are the merger with Pfizer resulting in inclusion of Advil in GSK’s product portfolio and higher sales of Voltaren Gel. On the other hand, Pfizer stood at the second rank owing to the increasing sales of Celebrex, a diversified product portfolio, and an established distribution channel. Competition in the market is increasing gradually as many new players are striving to enter into the market through new product launches and strategic collaborations.
The non-steroidal anti-inflammatory drugs market report offers a detailed analysis of numerous factors affecting the market. These include growth drivers, threats, opportunities, restraints, and key developments. Apart from this, the report further helps in analyzing, segmenting, and defining the market based on different segments such as disease indication, route of administration, and distribution channel. It also provides various key insights such as prevalence of major diseases for key countries, pipeline analysis, new product launches, key mergers& acquisition, joint ventures, and others.
To gain extensive insights into the market, Request for Customization
Value (USD billion)
By Disease Indication
By Route of Administration
By Distribution Channel
The value of the global market was USD 15.58 billion in 2019.
Fortune Business Insights says that the market is projected to reach USD 24.35 billion by 2027.
The value of the market in North America was USD 6.86 billion in 2019.
The market is projected to rise at a CAGR of 5.8% during the forecast period (2020-2027).
Arthritis is the leading segment in this market.
Rising prevalence of chronic pain and preference for NSAIDs over opioids are the key factors driving the market.
GlaxoSmithKline plc and Pfizer Inc. are the top players in the market.
North America is expected to hold the highest market share.
Research on developing selective COX-2 inhibitors is the key trend of the market.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry